Datapoint: Centene to Sell Two Specialty Pharma Businesses

Centene Corp. last week entered an agreement to sell two of its recent specialty pharmacy acquisitions, Magellan Rx and PANTHERx Rare, in separate deals totaling $2.8 billion. Magellan Rx will be sold to Blues PBM powerhouse Prime Therapeutics, while will go to a consortium of The Vistria Group, General Atlantic, and Nautic Partners, pending regulatory approval. Centene is currently the fourth-largest insurer in the U.S., with 21,213,845 members.

Source: AIS’s Directory of Health Plans

0

0

0 Comments

0

0

• Datapoint